The Medical Innovation Agenda for the 119th Congress
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Legal
Learn more about our Legal work.
Smith v. Terumo BCT (Colorado Court of Appeals) March 6, 2025
AdvaMed® filed an amicus brief in the case of Smith v. Terumo BCT, Inc. The case concerns whether the court should create a cause of action for asymptomatic plaintiffs, permitting…
Navigating Inbound Trade & Investment: Strategies for Medtech in the Era of Tariffs & Trade Legal and Policy Shifts
Akin will provide a CLE program covering the latest legal issues for inbound trade and investment, including the Trump Administration’s approach to trade policy and tariff issues, and strategies medical…
AdvaMed® Comment Letter to OIG’s Annual Solicitation for Safe Harbors and Special Fraud Alerts
AdvaMed urges OIG to modernize Anti-Kickback Statute safe harbors and issue a new fraud alert to support value-based care and expand access to medical technologies.
AdvaMed® Recommendations to CMS Regarding Sunshine Reporting Audits
AdvaMed®, the world’s leading medtech trade association, communicated to Centers for Medicaid & Medicare Services (CMS) recommendations regarding administration of the Open Payments program.
EcoFactor, Inc. v. Google LLC (US Court of Appeals) November 27, 2024
This case involves a patent infringement dispute between EcoFactor and Google, but the Court’s decision will reach every aspect of district court patent litigation in cases involving parties in every…
AdvaMed® Asks U.S. Court of Appeals to Support a Fair and Balanced Approach to Patent Damages
AdvaMed®, the Medtech Association, asked the United States Court of Appeals to support a fair and balanced approach to patent damages.
Edwards Lifesciences v. Meril Life Sciences (US Court of Appeals) November 18, 2024
The issue at hand is patent infringement and an overly broad interpretation of the Hatch-Waxman Act’s safe harbor. AdvaMed® pointed out that this would harm innovation. The decision has profound…